Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,shortTermInvestments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,currency,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,marketState,shortName,market,exchangeDataDelayedBy,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,EVFM,8964000.0,102838000,8507000,,-33414000,,-33426000,33653000,1018000,-41142000,-41142000,,,,,,12000,1857000,42999000,839000,7728000,,-33426000,-33426000,744013000.0,99784000.0,8964000.0,2073000.0,108748000.0,16000.0,15206000.0,-735065000.0,97000.0,1021000.0,46982000.0,68321000.0,12097000.0,95630000.0,3108000.0,26192000.0,10546000.0,7703000.0,,1826000.0,-1333000.0,52805000.0,-15933000.0,53728000.0,-2105000.0,-300000.0,-53577000.0,275000.0,-1049000.0,-194000.0,-623000.0,-5076000.0,-1333000.0,,27309000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620331200,1636369140,1636718400,-2.119,-0.96,-1.45,-0.58268964,0.017,0.82330555,0.021594465,0.02622898,1.5825797,-0.7376797,-0.46612483,86887824,-0.8801042,49.699997,15,America/New_York,EDT,-14400000,4,-4.7463374,0.8331 - 0.91,0.887,0.8495,0.8502,14,18,finmb_540843533,REGULAR,"Evofem Biosciences, Inc.",us_market,0,NCM,False,False,0.8449,1630510985,-0.042100012,0.8921,0.91,0.8331,4109285,NasdaqCM,"Evofem Biosciences, Inc.",USD,9149431,3505733,0.19090003,0.29189608,0.654 - 5.53,-4.6851,-0.8472152,0.654,5.53,1516233600,-0.49,,,5.53,0.654,0.8233,1.5826,9.15M,3.51M,102.84M,,142.83M,1.35%,29.87%,28.24M,7.04,20.51%,18.48%,28.72M,,,,,,0.00%,"Jan 17, 2018",,1:6,"Jan 17, 2018","Dec 30, 2020","Jun 29, 2021",0.00%,"-4,340.43%",-75.84%,-387.27%,3.41M,0.04,,78k,-147.27M,-150.07M,-2.1190,,46.98M,0.3,78.14M,871.75,1.40,0.02,-162.94M,-128.71M,Value,92130,Healthcare,147,10,10,"Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California.",San Diego,858 550 1900,CA,8,1609372800,1625097600,7,United States,http://www.evofem.com,86400,10,12400 High Bluff Drive,844 828 2010,Biotechnology,Suite 600
t-1,EVFM,-13638000.0,102838000,7118000,,-46152000,,-46151000,38353000,599000,-44872000,-44872000,,-1100000.0,,,,-1000,1105000,45977000,506000,-1280000,,-46151000,-46151000,687991000.0,107102000.0,-13638000.0,1549000.0,93464000.0,10000.0,19719000.0,-701639000.0,97000.0,1022000.0,45318000.0,75706000.0,12107000.0,80335000.0,2914000.0,25697000.0,8990000.0,6501000.0,,-4647000.0,-706000.0,28006000.0,14580000.0,28050000.0,-7158000.0,-7000.0,-34458000.0,195000.0,-1676000.0,-1847000.0,-37000.0,5088000.0,-956000.0,,4629000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620331200,1636369140,1636718400,-2.119,-0.96,-1.45,-0.58268964,0.017,0.82330555,0.021594465,0.02622898,1.5825797,-0.7376797,-0.46612483,86887824,-0.8801042,49.699997,15,America/New_York,EDT,-14400000,4,-4.7463374,0.8331 - 0.91,0.887,0.8495,0.8502,14,18,finmb_540843533,REGULAR,"Evofem Biosciences, Inc.",us_market,0,NCM,False,False,0.8449,1630510985,-0.042100012,0.8921,0.91,0.8331,4109285,NasdaqCM,"Evofem Biosciences, Inc.",USD,9149431,3505733,0.19090003,0.29189608,0.654 - 5.53,-4.6851,-0.8472152,0.654,5.53,1516233600,-0.49,,,5.53,0.654,0.8233,1.5826,9.15M,3.51M,102.84M,,142.83M,1.35%,29.87%,28.24M,7.04,20.51%,18.48%,28.72M,,,,,,0.00%,"Jan 17, 2018",,1:6,"Jan 17, 2018","Dec 30, 2020","Jun 29, 2021",0.00%,"-4,340.43%",-75.84%,-387.27%,3.41M,0.04,,78k,-147.27M,-150.07M,-2.1190,,46.98M,0.3,78.14M,871.75,1.40,0.02,-162.94M,-128.71M,Value,92130,Healthcare,147,10,10,"Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California.",San Diego,858 550 1900,CA,8,1609372800,1625097600,7,United States,http://www.evofem.com,86400,10,12400 High Bluff Drive,844 828 2010,Biotechnology,Suite 600
t-2,EVFM,1347000.0,102838000,5806000,,-40596000,,-40598000,30062000,17000,-35851000,-35851000,,-1082000.0,,,,2000,168000,36019000,151000,-4745000,,-40598000,-40598000,656827000.0,108621000.0,1347000.0,953000.0,109968000.0,8000.0,23359000.0,-655488000.0,97000.0,1048000.0,48892000.0,77283000.0,11190000.0,97730000.0,1317000.0,25211000.0,7162000.0,10641000.0,,4631000.0,-1421000.0,24917000.0,-7032000.0,110000.0,-15583000.0,-7000.0,-39079000.0,121000.0,-3098000.0,176000.0,-193000.0,6721000.0,-1421000.0,25000000.0,20447000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620331200,1636369140,1636718400,-2.119,-0.96,-1.45,-0.58268964,0.017,0.82330555,0.021594465,0.02622898,1.5825797,-0.7376797,-0.46612483,86887824,-0.8801042,49.699997,15,America/New_York,EDT,-14400000,4,-4.7463374,0.8331 - 0.91,0.887,0.8495,0.8502,14,18,finmb_540843533,REGULAR,"Evofem Biosciences, Inc.",us_market,0,NCM,False,False,0.8449,1630510985,-0.042100012,0.8921,0.91,0.8331,4109285,NasdaqCM,"Evofem Biosciences, Inc.",USD,9149431,3505733,0.19090003,0.29189608,0.654 - 5.53,-4.6851,-0.8472152,0.654,5.53,1516233600,-0.49,,,5.53,0.654,0.8233,1.5826,9.15M,3.51M,102.84M,,142.83M,1.35%,29.87%,28.24M,7.04,20.51%,18.48%,28.72M,,,,,,0.00%,"Jan 17, 2018",,1:6,"Jan 17, 2018","Dec 30, 2020","Jun 29, 2021",0.00%,"-4,340.43%",-75.84%,-387.27%,3.41M,0.04,,78k,-147.27M,-150.07M,-2.1190,,46.98M,0.3,78.14M,871.75,1.40,0.02,-162.94M,-128.71M,Value,92130,Healthcare,147,10,10,"Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California.",San Diego,858 550 1900,CA,8,1609372800,1625097600,7,United States,http://www.evofem.com,86400,10,12400 High Bluff Drive,844 828 2010,Biotechnology,Suite 600
t-3,EVFM,40210000.0,102838000,4099000,,-29897000,,-29899000,22018000,61000,-26056000,-26056000,,-700000.0,,,,2000,278000,26334000,217000,-3841000,,-29899000,-29899000,655092000.0,72117000.0,40210000.0,921000.0,112327000.0,8000.0,728000.0,-614890000.0,,1074000.0,86697000.0,65692000.0,9174000.0,102079000.0,1706000.0,,3164000.0,5427000.0,52000.0,-2202000.0,-297000.0,-603000.0,-6063000.0,110000.0,-36722000.0,-67000.0,-35822000.0,58000.0,-2040000.0,-1243000.0,-536000.0,5567000.0,-297000.0,25000000.0,36387000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620331200,1636369140,1636718400,-2.119,-0.96,-1.45,-0.58268964,0.017,0.82330555,0.021594465,0.02622898,1.5825797,-0.7376797,-0.46612483,86887824,-0.8801042,49.699997,15,America/New_York,EDT,-14400000,4,-4.7463374,0.8331 - 0.91,0.887,0.8495,0.8502,14,18,finmb_540843533,REGULAR,"Evofem Biosciences, Inc.",us_market,0,NCM,False,False,0.8449,1630510985,-0.042100012,0.8921,0.91,0.8331,4109285,NasdaqCM,"Evofem Biosciences, Inc.",USD,9149431,3505733,0.19090003,0.29189608,0.654 - 5.53,-4.6851,-0.8472152,0.654,5.53,1516233600,-0.49,,,5.53,0.654,0.8233,1.5826,9.15M,3.51M,102.84M,,142.83M,1.35%,29.87%,28.24M,7.04,20.51%,18.48%,28.72M,,,,,,0.00%,"Jan 17, 2018",,1:6,"Jan 17, 2018","Dec 30, 2020","Jun 29, 2021",0.00%,"-4,340.43%",-75.84%,-387.27%,3.41M,0.04,,78k,-147.27M,-150.07M,-2.1190,,46.98M,0.3,78.14M,871.75,1.40,0.02,-162.94M,-128.71M,Value,92130,Healthcare,147,10,10,"Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California.",San Diego,858 550 1900,CA,8,1609372800,1625097600,7,United States,http://www.evofem.com,86400,10,12400 High Bluff Drive,844 828 2010,Biotechnology,Suite 600
